Kris Barnette is a creative powerhouse—the President of All Good Marketing and an adjunct professor at Kent State—who brings a level of “swagger” to life science branding.

Kris is focused on turning Ontario, Canada, into a global commercial powerhouse in the life sciences.

Ontario has everything a biotech hub needs: world-class infrastructure, elite academic institutions, and incredible talent. However, Kris points out a “commercialization chokehold” that prevents the region from reaching global dominance. The science is often buried under layers of academic jargon and conservative positioning.

Kris is tackling this head-on with his upcoming project, The Ontario Life Science Founder Marketing Glow Up. It’s a guide designed to help PhD founders shift their mindset from “poster presentation” to “brand beast”.

One of the biggest hurdles for scientist-founders is the “curse of knowledge”. In academia, you’re taught to be conservative with data and open to endless debate. But as Kris explained, once you move from research to a venture, you are no longer just doing science—you are running a business.

Marketing isn’t just “mascara” or “bedazzle” you sprinkle on a product once it’s ready for the spotlight. It’s a muscle. It’s about charting a commercial path, building partnerships, and communicating value to three key audiences: investors, partners, and clinicians.

We talked about “Demand Gen Without Desperation,” a chapter in his book inspired by his work with Lee Jay Lowenstein at Stellar Scientific. Kris and Lee decided to inject some levity into the brand by creating the “Lab Llamas”—a family of characters like Lana Llama (Customer Service) and Leon Llama (Shipping).

While it might seem risky to use comic-book-style flyers in a conservative field, the data backed it up. Market research showed that 90% of customer sentiment was positive because people appreciated the friendliness and approachability. It proves that having a sense of humor doesn’t make you unprofessional; it makes you human.

Even for a veteran like Kris, with 30 years of marketing experience, putting yourself out there is hard. He admitted to a “reverse curse of knowledge”—feeling like if he knows something, everyone else must know it too, so why bother posting it on LinkedIn?.

But “invisible innovation” is a danger to any business. If your website is a “coming soon” page or your LinkedIn is silent, you’ve already lost. Kris had to overcome his own shyness to launch All Good Marketing in Canada, even navigating the hurdles of finding local talent to get his new site, allgoodmarketing.ca, live.

For U.S. companies looking to move north, Kris warns against simply “importing loud marketing”. The Canadian market is more risk-averse and relationship-driven. In Canada, trust is the primary currency; it’s earned slower, but it lasts much longer. His approach combines “Substance, Savvy, and Swagger” to help these companies get noticed without losing that essential human connection.

As a final surprise, Kris introduced his “aluminum shepherd,” Gizmo—a robot dog that will serve as his co-host for his upcoming 14-episode audio book podcast.

It was a fittingly creative end to the show. While this is the last episode of Life Science Marketing Radio, I am so grateful to the 200+ guests and the thousands of listeners who have joined me on this journey over the last 11 years.

Wishing you all the best.

Chris

At the Advanced Lateral Flow Conference, I spoke with Jeremy Elser, Head of Science Operations at Palantir and founder of Ship of Theseus, a biotech company tackling longevity and regenerative medicine. The name refers to the Greek thought experiment about replacing every plank on a ship over time, similar to Jeremy’s vision to keep rebuilding the human body, replacing the cellular “planks” so it stays functional indefinitely.

He’s focusing on restoring the body’s natural ability to regenerate using resident stem cells. Damage accumulates linearly throughout life, but aging accelerates when our capacity to replace that damage falters. His company aims to “re-up” that regenerative capacity, thus the metaphor of the Ship of Theseus .

Jeremy also spoke at the conference about using AI and large language models (LLMs) to break down complex scientific questions into smaller, solvable ones. This conversation was fascinating to me in regards to both the biology and the LLMs, discovering what’s possible with both.

Jeremy compared an LLM to an eager intern—smart, well-informed, but needing structure and direction. You can’t just hand it a huge problem like “design a new drug protocol” and expect perfection. But if you break that into smaller, ordered tasks like “find existing injury models,” “suggest positive controls,” “compare published protocols”, the system can produce remarkably intelligent, end-to-end workflows.

That approach mirrors how good scientists think. Start with clear purpose, choose the right model for the goal, and use well-established methods when you need confidence or novel ones when you want to show something better. It’s part strategy, part rigor, driven by intention. Using an LLM to see where your FDA submission meets (or doesn’t) guidelines seems a relevant example.

With respect to biology, Jeremy’s team applies that rigor to wound-healing research involving Hox genes, a class of master regulators that pattern the body during development. He explained how HoxA3, in particular, seems tailor-made for wound repair. It repolarizes macrophages from their inflammatory “angry” state to a regenerative one, promotes vascular growth, and helps skin cells migrate to close the wound. In his words, it “hits wounds in three different ways.” The same gene that once told your embryo where to put your head or feet can later tell adult cells how to heal. I find this phenomenon somewhat magical and hope to someday learn how that works at a molecular level.

On the AI front, Jeremy’s biggest insight was about preserving scientific context. He’s using AI to capture and structure what scientists actually do in the lab so knowledge doesn’t walk out the door when people leave. Instead of asking scientists to fill endless forms, the AI reads what they write, asks clarifying questions, and turns messy notes into structured data. The AI will generate every possible graph or chart based on the data, something most scientists would rather avoid. They can then find the ones that are interesting and discard the rest. Jeremy says,

 Yeah, that’s my bribe to the scientists ‘cause we enforce a little bit of structure. They have to obey the LLM when it asks for more information. So we try to compensate for that time by doing some of the grunt work that they don’t enjoy doing, like producing a bunch of charts.

Fair enough.

Jeremy wants AI not just to help scientists think faster but to help us see how it thinks so we can decide what to trust. His view is that LLMs already resemble a kind of brain: opaque, pattern-driven, capable of reasoning, but not always able to explain why. It turns out humans are no different. Jeremy shared an interesting example. You’ll have to listen to the episode for that.

Beyond the fascinating biology for me the takeaway (and in line with my own experience so far) is that the usefulness of LLMs goes way beyond answering questions or producing content. As I learned from Jeremy Utley of Stanford, using them as a teammate or collaborator is where the value lies.

This episode is a double from my visit to the Advanced Lateral Flow Conference.

Usability is Innovation: Atomo Diagnostics

Atomo Diagnostics set out more than a decade ago to solve a surprisingly human problem in diagnostics: complexity. Founder John Kelly describes how even the best rapid tests—validated in pristine lab environments—often fail when they reach the real world, where people have no training, and shaky instructions. That gap between laboratory precision and real-world usability has huge implications for reliability, trust, and ultimately regulatory approval.

Atomo’s core insight is simple: most errors in point-of-care testing aren’t biological—they’re behavioral. The accessories people use in the field (cheap pipettes, dropper bottles, uncalibrated parts) invite mistakes, and the more steps required, the higher the failure rate. Kelly and his team approached the problem the way a designer might: observe how real users behave, then engineer around human nature instead of fighting it.

To validate their approach, they went straight to the source—literally to the community—conducting studies in Africa with low-literacy users who received only picture-based instructions. “If it needs a lot of explanation, it’s probably not obvious,” Kelly notes. The goal: build a device that is self-explanatory and self-correcting.

Their solution, the Pascal platform, integrates every accessory needed to run a test—lancet, blood collection, and buffer reagent—directly into one cartridge. Instead of multiple steps and parts, users simply collect, press, and go. Each step is interlocked to prevent mistakes; for instance, the reagent button won’t activate until blood is correctly loaded. It’s engineering that enforces proper sequence, eliminating user doubt and waste.

Kelly describes how this design delivers the right volume, in the right order, every time—removing the “what if I did it wrong?” anxiety that undermines confidence in results. It’s the difference between a reliable diagnostic and a false sense of security.

Atomo’s HIV self-test—registered with the World Health Organization and distributed across Australia, Europe, and the UK—has demonstrated greater than 99% concordance between trained and untrained users. The company also supports a blood-based pregnancy test (approved in Europe and Brazil) that detects earlier than urine tests, and they’re now developing the world’s first active syphilis test, capable of distinguishing between current and previously treated infections.

What’s equally smart is their business model flexibility. Recognizing that many manufacturers already have validated lateral flow cassettes on the market, Atomo developed a “clip-on” usability upgrade that integrates their collection and buffer technology without requiring full retooling or revalidation—a bridge between old workflows and modern design.

Beyond infectious disease, Kelly sees growth in at-home wellness and chronic condition monitoring—everything from testosterone and thyroid tests to celiac screening. The platform’s adaptability makes it attractive for home use and clinical trials alike. One example: a pharmaceutical partner using Atomo’s device to monitor liver toxicity in patients remotely, reducing clinic visits from three times a week to “only when needed.” It’s better for patients, cheaper for healthcare systems, and faster for research.

The bigger story here is that usability is innovation. Kelly’s approach turns workflow design into a driver of impact. Instead of chasing exotic chemistry, Atomo focused on reliability and trust—two things that ultimately decide whether a test makes it into people’s hands.

As diagnostics and healthcare move increasingly into the home, Atomo’s design philosophy feels ahead of its time. If the pandemic taught us anything, it’s that people can and will take responsibility for their health—if we give them tools that make sense.

Pitch Competition Finalist: EAZEBIO

I also sat down with Ying Chen, founder of EAZEBIO, one of the Innovation Award finalists. Her company’s portable strip-based diagnostic platform combines CRISPR and AI to bring precision health to everyone, especially in low-resource settings.

The Problem: Reactive Healthcare

Ying opens by explaining the fundamental flaw she sees in today’s healthcare system—it’s reactive. We wait for symptoms to become severe before acting. EAZEBIO’s mission is to shift the paradigm toward proactive, precision healthcare, emphasizing early detection and personalized intervention. Her team focuses on diseases often overlooked at the root-cause level—metabolic, autoimmune, and cardiovascular conditions.

Their aim is to bridge the gap between scientific breakthroughs and universal access, translating biomarker data into actionable health insights. As Ying puts it, “We hope proactive, personalized care can provide health equity for everyone, no matter where they live.”

Ying’s background is a blend of pediatrics, research science, and business—she holds both a PhD and an MBA. Her experience inspired her to adapt the power of CRISPR from the lab to the home.

In their prototype for sepsis detection, EAZYBIO’s system uses CRISPR to identify antimicrobial resistance genes—the genetic clues that reveal which pathogen is causing an infection. The test also detects human protein biomarkers, providing a two-layered view of infection and host response.

Here’s how it works:

* The CRISPR complex acts like a molecular “scissor,” recognizing and cutting specific DNA or RNA sequences associated with infection.

* These sequences are tagged with a cortisol-based reporter. When the CRISPR cut happens, cortisol is released.

* The released cortisol binds to split reporter proteins, generating a visible signal on a lateral flow strip.

* An AI-powered app then reads and interprets the signal into a semi-quantitative result.

This approach achieves roughly 300x signal amplification compared to conventional lateral flow assays—crucial for fast, reliable results.

Sepsis is notoriously time-sensitive; treatment delays of more than three hours can dramatically increase mortality. Ying emphasizes that EAZEBIO’s platform could enable clinicians to identify pathogens and select the correct antibiotic within one hour—a potentially life-saving improvement.

While sepsis is their initial target, the underlying platform is modular and scalable, enabling future multiplexing for 3–5 pathogens per test. Beyond acute disease, the same technology could support early cancer detection and wellness testing, making high-quality diagnostics as easy as a home pregnancy test.

Ying speaks with humility about being a finalist at ALFC, but it’s clear the recognition validates EAZEBIO’s bold vision. The conference gave her valuable exposure to peers across R&D and manufacturing, as well as insights into where diagnostics are heading over the next decade.

Her takeaway? Collaboration and accessibility matter just as much as innovation. “It’s not just technology—it’s about bringing care to everyone, whether they live in a big city or a rural village.”

Carter Mitchell, Chief Scientific Officer at Kemp Proteins, brings scientific rigor and an artist’s imagination to the world of protein design and production. In this episode, recorded at the Advanced Lateral Flow Conference, we explore how his company is pushing the boundaries of protein expression, quality, and analysis using tools that merge machine learning, automation, and human creativity.

A company reborn through precision and innovationKemp Proteins has deep roots in recombinant protein production, tracing back over 30 years to a company that began with insect-cell expression systems. After a rocky acquisition phase, the company was revived with renewed focus under CEO Mike Keefe, this time with a modern quality management system and new emphasis on antibodies and engineering solutions for diagnostics, therapeutics, and vaccines.

Carter, a self described protein nerd, joined around that time, bringing expertise in structural biology, protein engineering, and quantitative analytics and a mission to integrate AI into the company’s core processes.

Why insect cells still matterI knew that people used insect cells but I didn’t know why. Mitchell explains how insect cells, long used in protein production, still offer unique advantages. Unlike E. coli, insect cells can perform post-translational modifications, such as glycosylation—key for producing proteins that resemble their natural human counterparts. While mammalian systems like HEK293 have since made expression “paint-by-numbers” simple, Carter notes that insect systems still excel when complexity and authenticity matter. “It’s about having multiple expression capabilities,” he says, “so you can choose the right one for the problem at hand.”

Four questions that guide every projectCarter’s approach to solving client challenges starts with four questions:

* What is the protein?

* What information is available?

* What’s the intended use?

* What’s the scale?

From there, the team tailors both the process and the system to ensure reproducibility and regulatory readiness, whether the goal is a diagnostic reagent or a therapeutic protein. As an aside, manufacturing kilograms of protein still blows my mind.

As Carter puts it: “Regulators don’t want to see a smear on an SDS page. We think like regulators, anticipate their questions, and design out variability before it becomes a problem.”

From data lake to digital expert: ProtIQThe centerpiece of Carter’s innovation is ProtIQ, an internal expert system that combines structured data, AI models, and domain expertise into a 200–300-page report for every target protein. Initially, these reports were for experts, but Carter’s team is now transforming them into an interactive chatbot interface so anyone on the team can query the data conversationally.

“If a technician can ask, ‘What’s the isoelectric point?’ or ‘Does it have a secretory tag?’ and get an immediate answer, they’re empowered,” he says.It’s part of a broader effort to turn technicians into scientists, helping them engage more deeply with data, notice anomalies early, and contribute to process improvement.

Predicting protein liabilities before they happenUsing sequence analysis and AI-assisted visualization, Kemp Proteins can predict potential degradation sites or stability issues before production even begins. Carter’s team also models how viral variants like influenza strains might evolve over time, identifying changes in glycosylation patterns that could impact diagnostic binding. “We’re actually collaborating with the FDA on this,” he adds.

When science meets artCarter looks at protein structure like art. A lifelong painter and flamenco guitarist, he traces his fascination with structure to his mother’s art studio and his childhood encounters with crystals in Texas soil. That visual mindset drives how he thinks about molecules: “Art flattens multi-dimensional space to describe motion. That’s what we do in AI and machine learning, flattening complexity into something interpretable.”

Anis Fahandej-Sadi is building two businesses. He is the founder of TLDR Biotech, a daily newsletter that condenses life science news into a quick, skimmable format, and creator of Science 2 Sales, a service designed to help biotech companies accelerate business development. In this conversation, Anis opens up about his career journey, the lessons he’s learned in building content-driven businesses, and his perspective on where life science marketing is heading.

The Birth of TLDR Biotech

Anis started TLDR Biotech with this idea: build the thing you wish existed. With his background in sales and BD, he saw how overwhelming it was to track 10+ news sources every day just to stay informed. So he created a newsletter that captures the good, the bad, and the ugly (those are literally the categories) in biotech news, sprinkled with memes and GIFs for personality.

The format drove strong reactions. Some folks loved the humor, but hated the GIFs. However, strong reactions mean you’re creating something memorable. Strive to make a product where you can say, “It’s not for everybody.” Nevertheless, growth stalled early on, leading Anis to pause the newsletter and retool his approach.

Anis shared his struggles around finding product-market fit, admitting he initially took the wrong approach by treating it as a full-time venture too early. He had to find the product that suited him. After a strategic pause in May, he restructured the backend to create content more efficiently while maintaining quality. Now he is focused on organic growth through LinkedIn and expanding into interview content to expand his reach.

From Chemistry to Business Development

After earning a master’s in chemistry, he taught English in Korea, then pivoted into sales roles for life science companies like Cytiva and OmniaBio. Business development roles are a great fit for scientists who crave variety and human interaction, but the transition isn’t easy. There’s often little formal training, so one has to learn prospecting, discovery calls, and pipeline management on the fly. His advice for scientists considering sales: leverage LinkedIn, embrace continuous learning, and be clear on why you want to leave the lab.

Science to Sales: A New Kind of BD Support

His current venture, Science to Sales, tackles the pain of BD reps spending too much time on cold outreach instead of moving real deals forward. His team takes on prospecting, cold emails, LinkedIn outreach, and calls, so client BD teams can focus on high-value work. The approach begins with deep research into the client’s ideal customer profile, growth goals, and messaging. But the most interesting angle is pairing outbound prospecting with executive-driven LinkedIn content. The platform is evolving beyond corporate messaging to more authentic, personal storytelling.

Why LinkedIn Needs Personality

The old model of corporate-only content is dead. The future is personality-driven, with executives and BD reps building authentic, active profiles. He points to examples like Steve Harvey of Camena Biosciences and Philippe Baaske at NanoTemper as models for how thought leadership and “building in public” can humanize companies and create inbound traction. As a clear signal of where the market is going, even companies like PayPal are hiring full-time staff to manage CEO content.

Short-form video and personality-driven LinkedIn posts are no longer optional. They’re becoming essential. And while it’s not easy (Anis admits to his own hesitations about video), the payoff is familiarity that turns cold calls into warm conversations.

Your deepest insights are your best branding. I’d love to help you share them. Chat with me about custom content for your life science brand. Or visit my website.

Tino Chow’s career spans three worlds—military operations in Singapore, industrial design at Rhode Island School of Design, and entrepreneurship. That mix has shaped his work at Giant Shoulders, where he helps challenger brands in medtech, venture capital, and startups bring innovations to market.

It takes more than a great product and strong marketing. Without a sustainable business model, impact fades. For startups, the challenge is bigger. You’re new, unproven, and likely challenging the status quo. Your first hurdle isn’t your tech, it’s earning trust.

Tino’s biggest lesson after coaching 350+ founders: in addition to selling your innovation, you’re selling yourself. Investors and partners must decide if they can trust you before they ever dig into the data. That’s where the “superhero origin story” comes in. Peter Parker didn’t become Spiderman when the spider bit him. He became a superhero only after he discovered how to use his new powers for good. He found his purpose. Founders who can share that moment connect on a human level and settle what Tino calls the “lizard brain”, the audience’s instinctive fight-or-flight filter. Purpose is what will convince an investor that you’ll stick with the business when things get tough. (And they will).

It reminded me of a famous psychology study where people asked to cut in line at a copy machine. When they gave a reason — even something obvious like “because I need to make copies” — people were far more likely to let them in. The reason didn’t have to be good, it just had to exist. Now imagine what your origin story can do when it’s actually rooted in purpose. It gives people a reason to believe in you before they’ve even looked at your numbers. Superhero tip: Always use your powers for good.

He draws on his military experience to explain why creativity and discipline aren’t opposites. In elite teams, strict process frees you to improvise under pressure—just like in music, where mastery of fundamentals enables jazz improvisation. For startups, that process-driven creativity is what builds lasting brands.

Many technical founders resist storytelling, assuming data will speak for itself. But as Tino points out, ten people can look at the same numbers and draw ten conclusions. Without a clear narrative, your audience may misinterpret the story your data tells. Once founders see this, they start to value narrative control—and they often see fundraising improve.

The episode is full of practical takeaways:

* Lead with why you care, not how your tech works.

* Control the narrative so your data supports your story.

* Challenge yourself to ask “naïve” questions—they can lead to surprising insights.

* Trust-building begins the moment you open your mouth. Make it count.

Your deepest insights are your best branding. I’d love to help you share them. Chat with me about custom content for your life science brand. Or visit my website.

Tiffany Payne recently attended the American Society of Mass Spectrometry meeting—just two weeks after being laid off—and received a badge with "NONE" printed in giant letters under “Company.”

She could only laugh to keep from crying. It’s sometimes hard to separate our job from our identity. Tiffany turned it into a conversation starter: “I’m the CEO of None Industries—offering nothing to no one, anywhere.” Humor not only helped her deal with the sting of unemployment but also opened doors to conversations with peers at the event who had faced the same experience. Her badge was now a symbol of honesty and resilience.

Here is Tiffany’s perspective: Layoffs are hard, but the fear of being laid off can be even worse. Once you’re on the other side of it, you have control again—you can decide what you value, what work means, and how you want to show up in the world. For Tiffany, this led to founding Veris Marketing, rooted in clarity about what marketing really is.

Defining Marketing

Tiffany’s definition of marketing is far from the “Mad Men” clichés of catchy slogans and glossy brochures.

“Marketing isn’t about convincing people to buy something they don’t need. It’s about understanding their real problems and matching them with the right solution.”

She shared a story about working with a lab that developed a faster drug test. Instead of focusing on technical specs, she framed the story around the human stakes: the child protective services administrator choosing between a lab that returns results in weeks versus one that can respond in days. If you are a child in a home with someone abusing drugs, that matters. Good marketing starts with empathy and storytelling.

On Being an Upstander

Tiffany is also vocal about values. She celebrates companies that stay committed to diversity, equity, and inclusion (DEI), even when it’s not mandated or trendy, calling them “upstanders.” Inspired by her daughter’s experience at San Francisco Pride, she encourages companies to lead with integrity, not fear.

“If you drop your DEI policy when the pressure is off, what does that say about what you really believe?”

I tend to agree. You can choose to have a policy or not, but the companies that dropped their initiatives as soon as it became convenient revealed something about themselves.

Advice for Job Seekers

Tiffany has heard some people advising some job seekers to “hide” their age, gender, or identity on resumes. While it’s certainly understandable in the current environment, she says:

“If you have to hide who you are to get the job, is that the place you really want to work?”

In addition, do we want to give more power to the companies that are doing that?

I appreciate Tiffany’s vision for the world. She is passionate about building alternative paths—small, connected businesses that can thrive without relying on corporate gatekeepers.

“Imagine creating a company where you get to pick all your coworkers. That’s the dream.”

If you or someone you know has been dealing with the struggles of unemployment, this episode is worth listening to and sharing.

Your deepest insights are your best branding. I’d love to help you share them. Chat with me about custom content for your life science brand. Or visit my website.

When you're selling something truly new, you're not just fighting for market share – you're fighting to create a market that doesn't exist yet. A big part of that battle is figuring out your sales process. Chris Morrison from ViaVerus and Brian Jamieson from Diagnostic Biochips shared their experience on this week’s episode.

Chris Morrison introduced the "innovation death spiral." It goes like this: A startup gets early validation from one big customer. They get excited (who wouldn’t?) and build their entire go-to-market strategy around that single success. Then... silence. The market doesn't respond as expected, so they double down on their approach, burning through resources until there's nothing left.

This pattern is particularly dangerous because that first success feels so validating. As Chris put it, finding one customer isn't a repeatable process, which is what is needed for long-term success.

Diagnostic Biochips provides an example of navigating these treacherous waters. They've developed technology that can read the "ones and zeros" of brain activity. If you want to learn more about the science, make sure you listen to the full recording. It's cool stuff that could revolutionize how we understand and treat conditions like Alzheimer's, schizophrenia, and epilepsy.

If you aren’t subscribed, now might be a good time…

But here's the catch: When you're that innovative, your biggest challenge isn't competition – it's teaching the market what's even possible.

The Discovery-Based Sales Process

Traditional sales processes are execution-based: You have historical data, known customer needs, and established patterns to follow. But what do you do when none of that exists?

Morrison and Jamieson's approach reveals a framework that any tech startup can learn from:

Instead of assuming they knew their market, they tested their initial assumption about big pharma being their primary customer. When that didn't pan out, they pivoted quickly rather than forcing a fit.

They discovered their sweet spot wasn't with big pharma or pure academic research, but with translational research organizations – the groups that bridge the gap between basic science and practical applications.

Rather than trying to educate the market about their technology's potential, they focused on identifying existing problems their technology could solve today.

One customer isn't validation – it's an anomaly. And two customers are just two different cases. According to Morrison, for complex B2B sales like Diagnostic Biochips, you need 10-20 customers before you can start seeing genuine patterns emerge in your sales process.

Developing a repeatable sales process isn't a single task – it's a series of staged discoveries:

* Market Entry Point: Identifying where your technology connects with immediate, funded problems

* Messaging: Finding the language that resonates with early adopters

* Lead Generation: Developing tactics that consistently bring qualified prospects

* Sales Process: Building the steps that convert interest into purchase

* Customer Success: Creating the bridge from purchase to satisfied customer

You can't skip steps. You need to complete each stage before moving to the next.

Perhaps the most interesting tension revealed in our conversation was what Brian Jamieson called "the funny combination between urgency and patience." Revolutionary technology creates natural urgency – you're sitting on something that could change the world. But rushing the process of finding your market fit can kill even the most promising innovation.

I actually thought there was an opportunity to educate the market on the gap between patch-clamp studies and animal behavior. Chris emphasized that startups don't have the luxury of educating markets. Instead, find where your innovation solves an existing, recognized problem.

The goal is to find messaging that makes customers pull you toward their problems rather than pushing your solution onto them.

As Chris noted, what typically takes three years can be compressed to 18 months with the right approach – but it can't be compressed to three months, no matter how hard you push.

Diagnostic Biochips' technology could fundamentally change how we understand and treat brain disorders. But that potential can only be realized if they successfully navigate the path to market. I often wonder how many amazing technologies end up on the scrap heap, not because of science but because of poor timing or strategy.

Launching truly disruptive technology is "probably one of, if not the hardest thing to do in business." But with a disciplined approach to discovering your repeatable sales process, it's not impossible. It's a matter of having the wisdom to be patient and the drive to stay urgent while you figure it out.

Your deepest insights are your best branding. I’d love to help you share them. Chat with me about custom content for your life science brand. Or visit my website.

When Joachim Eeckhout says he started small, he’s not kidding. He and a friend began curating biotech news from a Paris dorm room, eventually launching LaBiotech.eu, a media brand that became a trusted voice in European biotech. What caught my attention is how they learned the landscape: by biking across France with a camera, interviewing CEOs, and turning it into a documentary. That’s how they built credibility and a network from scratch. As a fan of cycling, science and documentary filmmaking, that sounds like a dream job to me. Or me 40 years ago…

That kind of storytelling, doing something unexpected and human, creates lasting connections. In our attention economy, Joachim’s approach stands out. He now runs The Science Marketer, helping life science companies do smarter marketing with a voice and personality.

Content doesn’t need to be flashy. But it does need to be authentic, consistent, and personal. Joachim suggests starting with what you would actually want to see yourself. That’s how you find your edge or your angle.

If you aren’t subscribed, now might be a good time…

We dug into the mechanics of content-led growth: how podcasts and newsletters aren’t just media channels—they’re trust-building engines. When someone hears your voice regularly or reads your thoughts in their inbox each week, you go from being a company name to a known entity. Familiarity builds comfort, and comfort builds trust. And unlike a sales call, this kind of content scales. It creates what Joachim calls “a simple funnel”. You share your perspective, your expertise, and a bit of your personality, and over time, people move closer to working with you.

Funnels have gotten a bad name lately. Nobody wants to feel like a lead. So how do you build one without turning people off? The goal is to show up with something valuable, consistently, and let the content do the work. This is especially important for founders and CEOs. The ones who are willing to show up, not just to talk about the science, but to let people see who they are, how they think, and what kind of culture they’re building, stand out. Customers don’t just pick a service; they pick a team. The value of good content is letting them get to know yours without pressure.

Joachim shares my love of repurposing. Too many companies make a great webinar, record a brilliant interview, or write a strong article and it’s one and done. They move on. But that single piece of content can become the seed for a dozen others. Joachim talked about how he helps clients turn webinars into PDFs, transcripts into blog posts, clips into LinkedIn videos, even media pitches that include actual footage of someone making their point, instead of a generic quote in a press release.

We both agree that posting content more than once on the same platform is a mental hurdle more than a real one. Most people won’t see your post the first time. And if they do, they probably won’t remember it. So why not reshare it? Especially if it was good. Posting the same content again weeks or months later isn’t lazy. It’s efficient and effective.

Joachim brought up Plasmidsaurus, a company that markets seriously essential biotech services by being obsessed with dinosaurs. It works because it’s memorable, and it doesn’t compromise the quality of the science.

The whole conversation was a reminder that in biotech, seriousness doesn’t have to mean boring. Passion, creativity, and a little risk-taking can go a long way in earning trust and growing your brand.

Your deepest insights are your best branding. I’d love to help you share them. Chat with me about custom content for your life science brand. Or visit my website.

Nick Clare is a co-founder of Succession Bio and co-host of the SalesDNA podcast. I recently spoke to Harrison Wade, the other co-founder here. Nick's journey into sales wasn't a planned career move. It was the result of "fear and desperation," as he put it.

Nick was working as a scientist in the lab when his wife was 14 weeks pregnant with their third child. 20 days before Christmas, he was made redundant. Ouch. During his job search, he interviewed with a company where the CEO and CBO offered him two positions - field application scientist or lab manager. Nick, thinking about his growing family and financial needs, asked the most direct question possible: "Which one pays more?" The CBO immediately claimed him for the sales side, recognizing the money motivation that's so crucial in sales.

Nick was honest about his initial resistance. He spent the first six months looking for another job because he was a scientist, not a salesperson. But eventually he realized he wasn’t finding anything he wanted because he actually loved what he was doing. Now he runs a company that teaches sales, selling sales itself. Men make plans and the universe laughs…

I asked about the distinction between sales and business development, something it seems everyone describes differently. Nick's definition is pretty simple: sales is about selling something that already exists - a widget, service, or software - while BD is about selling partnerships to develop something new together. CROs are kind of a hybrid. He pointed out that BD professionals often lag behind in their processes compared to traditional salespeople. They rely heavily on networking but don't utilize the same systematic lead generation and pipeline management that sales teams do.

That brought us into a discussion of cold email (Yikes), but Nick and Harrison's LinkedIn posts have been helping me get over that fear. Nick's perspective is liberating (and reflects the truth): he challenged me to think of a single email from the past two weeks that annoyed me enough to actually do something about it. I couldn't. His point was we only remember emails that resonate positively with us. Everything else just gets deleted and forgotten. We're so worried about negative consequences that we miss the fact that most people won't even notice our outreach, and when they do, it's usually positive.

Nick has a "10 a day" rule from when he managed sales teams - spend five minutes researching each person and reach out to 10 people daily. That's less than an hour of work that results in 200 outreaches per month. That math should be sufficient when you think about pipeline impact.

We have to talk about how Nick uses Notebook LM for sales research. I'm a huge fan of this Google AI tool myself, and Nick's applications are brilliant. He uploads company websites and generates mind maps to visualize all their products and propositions, perfect for visual learners like him, preparing for discovery calls. Even better, he creates AI-generated podcasts from the research materials that he can listen to while driving or multitasking. The fact that you can now interrupt these AI podcasts to ask questions makes it even more powerful.

I shared how I've been using Notebook LM with 10 years of podcast transcripts, creating a searchable knowledge base where people can ask questions about life science marketing and get specific insights from past guests. Nick's using it to help his daughters with homework, having them listen to AI-generated podcasts about complex topics before tackling assignments.

If you are AI resistant, I think you have to recognize what’s coming, whether you like it or not. You can be part of your own plan or part of someone else’s. Quick aside: When I was a kid, my dad had a gag where he had a telephone handset (with a spiral cord pinned inside his jacket. He had a ringer in his pocket that sounded like a phone. He’d pull out the handset and say, “It’s for you.”

What used to be a laugh is now an indispensable reality. Fast forward and this morning I’m using advanced voice mode to have a conversation with ChatGPT about content creation while I’m on a walk. You get the picture.

Nick talks to ChatGPT while driving to customer calls, essentially having a conversation with an AI teammate about strategy and approach. He even created a custom GPT called "Pocket Nick Nick" loaded with his company's public data, so he could access specific information during customer calls in real-time.

What I appreciated most was his practical, no-nonsense approach to both sales and AI. He's not afraid to be direct about money (which served him well in that initial interview), he's systematic about prospecting, and he's embraced AI as a genuine productivity multiplier rather than viewing it as a threat. I’m not making or following predictions about AI making us dumber or smarter or taking our jobs. The only thing I’m sure of is that people will use it.

Nick's story also highlights something I see frequently in our industry - scientists who discover they love the business side of science. There's something powerful about being able to share science broadly rather than going deep into one narrow research area. Nick used a great analogy about being on a boat viewing the horizon versus investigating the Mariana Trench.

This conversation energized me around several things: being more systematic about outreach (those 10 people per day), using AI more creatively in my work, and thinking about BD versus sales more clearly. Nick's journey from reluctant scientist to sales leader shows that sometimes the best career moves come from necessity rather than planning, and that embracing change - even when it feels uncomfortable - can lead to unexpected fulfillment.